Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Huan-Wei Zheng

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Zhonghua Gan Zang Bing Za Zhi = Zhonghua Ganzangbing Zazhi = Chinese Journal of Hepatology|December 13, 2007
[Interferons for treating chronic hepatitis B]Ji-Dong Jia, Huan-Wei Zheng
Zhonghua Gan Zang Bing Za Zhi = Zhonghua Ganzangbing Zazhi = Chinese Journal of Hepatology|October 6, 2011
[Chronic hepatitis C combined with Sheehan's syndrome: a case report]Wei Wang, Huan-wei Zheng, Gui-fang Ren, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|December 20, 2011
Hepatitis B virus particles preferably induce Kupffer cells to produce TGF-β1 over pro-inflammatory cytokinesHai Li, Huan-Wei Zheng, Hui Chen, et al.
Hepatobiliary & Pancreatic Diseases International : HBPD INT|March 29, 2022
Impact of Fuzheng Huayu tablet on antiviral effect of entecavir in patients with hepatitis B cirrhosisDan-Ying Cheng, Zhi-Min Zhao, Gang Wan, et al.
Plos One|April 9, 2014
Regulatory phenotype, PD-1 and TLR3 expression in T cells and monocytes from HCV patients undergoing antiviral therapy: a randomized clinical trialShan-shan Su, Huan He, Ling-bo Kong, et al.
The Journal of International Medical Research|June 23, 2016
Tim-3 suppression combined with TLR3 activation enhances antiviral immune response in patients with chronic HCV infectionYue-Min Nan, Shan-Shan Su, Xue-Min Niu, et al.
Zhonghua Gan Zang Bing Za Zhi = Zhonghua Ganzangbing Zazhi = Chinese Journal of Hepatology|May 14, 2013
[Study of using an individualized treatment strategy to treat patients with chronic hepatitis C]Yue-Min Nan, Huan-Wei Zheng, Dian-Xing Sun, et al.
Journal of Viral Hepatitis|May 9, 2020
Clinical features of hepatitis B patients at immune-tolerance phase with basal core promoter and/or precore mutationsMin-Ran Li, Zun-Gui Xu, Jian-Hua Lu, et al.
Oncotarget|January 5, 2017
Serum hepatitis B core antibody titer use in screening for significant fibrosis in treatment-naïve patients with chronic hepatitis BMin-Ran Li, Huan-Wei Zheng, Jian-Hua Lu, et al.
Journal of the Chinese Medical Association : JCMA|August 26, 2018
Correlations between serum hepatitis B surface antigen and hepatitis B core antibody titers and liver fibrosis in treatment-naïve CHB patientsMin-Ran Li, Huan-Wei Zheng, Shun-Mao Ma, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Zhonghua Gan Zang Bing Za Zhi = Zhonghua Ganzangbing Zazhi = Chinese Journal of Hepatology|December 13, 2007
[Interferons for treating chronic hepatitis B]Ji-Dong Jia, Huan-Wei Zheng
Zhonghua Gan Zang Bing Za Zhi = Zhonghua Ganzangbing Zazhi = Chinese Journal of Hepatology|October 6, 2011
[Chronic hepatitis C combined with Sheehan's syndrome: a case report]Wei Wang, Huan-wei Zheng, Gui-fang Ren, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|December 20, 2011
Hepatitis B virus particles preferably induce Kupffer cells to produce TGF-β1 over pro-inflammatory cytokinesHai Li, Huan-Wei Zheng, Hui Chen, et al.
Hepatobiliary & Pancreatic Diseases International : HBPD INT|March 29, 2022
Impact of Fuzheng Huayu tablet on antiviral effect of entecavir in patients with hepatitis B cirrhosisDan-Ying Cheng, Zhi-Min Zhao, Gang Wan, et al.
Plos One|April 9, 2014
Regulatory phenotype, PD-1 and TLR3 expression in T cells and monocytes from HCV patients undergoing antiviral therapy: a randomized clinical trialShan-shan Su, Huan He, Ling-bo Kong, et al.
The Journal of International Medical Research|June 23, 2016
Tim-3 suppression combined with TLR3 activation enhances antiviral immune response in patients with chronic HCV infectionYue-Min Nan, Shan-Shan Su, Xue-Min Niu, et al.
Zhonghua Gan Zang Bing Za Zhi = Zhonghua Ganzangbing Zazhi = Chinese Journal of Hepatology|May 14, 2013
[Study of using an individualized treatment strategy to treat patients with chronic hepatitis C]Yue-Min Nan, Huan-Wei Zheng, Dian-Xing Sun, et al.
Journal of Viral Hepatitis|May 9, 2020
Clinical features of hepatitis B patients at immune-tolerance phase with basal core promoter and/or precore mutationsMin-Ran Li, Zun-Gui Xu, Jian-Hua Lu, et al.
Oncotarget|January 5, 2017
Serum hepatitis B core antibody titer use in screening for significant fibrosis in treatment-naïve patients with chronic hepatitis BMin-Ran Li, Huan-Wei Zheng, Jian-Hua Lu, et al.
Journal of the Chinese Medical Association : JCMA|August 26, 2018
Correlations between serum hepatitis B surface antigen and hepatitis B core antibody titers and liver fibrosis in treatment-naïve CHB patientsMin-Ran Li, Huan-Wei Zheng, Shun-Mao Ma, et al.
Pageof 2